Clicky

This stubborn virus has remained defiant to vaccine treatments in the past, but if Frazer’s gambit proves successful, we’ll have not only the world’s first vaccine against the disease, but we could also see the first long-awaited DNA vaccine for humans. Restricted Access Oops, it looks like you don’t have a valid subscription to this content. National Institutes of Health grant AI030731, Lab Core, supported development of the HSV-2 PCR. meaning our herpes therapeutic vaccine has huge market potential,” he said. Coridon’s Herpes vaccine, which was recently announced to be 100% effective in protecting animals against Herpes Simplex Virus 2 infection, incorporates the NTC8485 antibiotic-free expression vector. Each group was vaccinated either with the Coridon HPV mixed DNA vaccine, with E7 protein with adjuvant that served as the control model, or received no vaccination at all. This vaccine has something quite different driving it, said Professor Frazer, a former Australian of the Year.

There is no way to say without a doubt that you are not pregnant but it is unlikely. Monitoring visits will take place 24h and 48h after vaccination and thereafter the subject will keep a diary card for another 5 days. HPV is associated with several human cancers, most notably cervical cancer. Major shareholder in Coridon, Allied Healthcare Group (ASX: AHZ) is working with Professor Frazer to assist in the commercialisation of his work. Coridon’s technology has been developed to stimulate not only a strong antibody response but also a robust cellular immune response and is particularly suited to the development of therapeutic vaccines. Part of Coridon’s current program is targeting the development of a follow-up vaccine to this, offering therapeutic as well as preventative qualities. A promising new clinical trial for a HSV2 vaccine just opened up for human research testing and is looking for volunteers.


Frazer 0 David M. [71] Another study by Yih et al. Any or all of our forward-looking statements here or in other publications may turn out to be incorrect. ”I thought it was a cut,” he said. Having achieved this milestone, Coridon has now secured additional funding from major investor Allied Healthcare Group and plans to commence manufacturing and undertake formal pre-clinical safety studies before testing the vaccine in a Phase I clinical study. Coridon’s Herpes vaccine, which was recently announced to be 100% effective in protecting animals against Herpes Simplex Virus 2 infection, incorporates the NTC8485 antibiotic-free expression vector. Product development is currently focused on herpes virus vaccines.

To gain full access to the content and functionality of the AdisInsight database try one of the following. Researchers looked at emergency room records and hospital visits for 60 days after each dose given to the 189,629 females in the study. National Institutes of Health grant AI030731, Lab Core, supported development of the HSV-2 PCR. Coridon was established to commercialise new vaccine technologies developed by Prof Ian Frazer, the developer of the Gardasil cervical cancer vaccine, and his team at the University of Queensland. An Australian scientist who successfully invented the cervical cancer vaccine is working on new treatments for the herpes simplex virus. is a leading provider of DNA plasmid manufacturing and development services for DNA vaccine and gene therapy research. Supporting the growth is Allied Healthcare’s profitable medical device sales business which grew revenues by 65% in the current year.

Dr. The optimized vaccines, subcloned into a vector suitable for use in humans, also provided a high level of protection against the establishment of ganglionic latency, an important correlate of HSV reactivation and candidate endpoint for vaccines to proceed to clinical trials. These results were presented at the 5th Vaccine and ISV Annual Global Congress in Seattle earlier this month. Although there is no cure for herpes, certain medications can help prevent or shorten outbreaks. Herpes simplex virus type 2 (HSV-2) is the primary cause of genital herpes, a common sexually transmitted disease with at least 40 to 60 million. The study aimed to mimic the exposure of women to semen from HIV-infected men, although the viral dose of each of these 7 animal challenges represented about 70,000 times the average human HIV dose passed during sexual intercourse from an HIV-infected male to an uninfected female. Sullivan, Ph.D., Vical’s Executive Director of Pharmaceutical Sciences, is scheduled to present in the Keynote Forum at 9:30 a.m.

Coridon requested VGXI use HyperGRO™ fermentation technology to satisfy their project’s unique requirements. VGXI entered into a manufacturing agreement with Coridon Pty Ltd earlier this year to manufacture Coridon’s Herpes Simplex Virus 2 DNA vaccine for their upcoming Phase I clinical trial. Some advancement on the herpes vaccine front: San Diego biotech Vical recently kicked off a Phase 1/2 trial of its Vaxfectin genital herpes vaccine – a therapeutic inoculation that’s melded vaccine and DNA technologies. If the child is in kindergarten or a nursery, parents will be sooner or later confronted with a disease that mainly occurs repeatedly in the summer months and the parents can imagine little.